| Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s disease (AD): from risk factors to therapeutic targeting YN Paudel, E Angelopoulou, C Piperi, I Othman, K Aamir, MF Shaikh Cells 9 (2), 383, 2020 | 166 | 2020 |
| Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling YN Paudel, E Angelopoulou, C Piperi, VRMT Balasubramaniam, ... European journal of pharmacology 858, 172487, 2019 | 153 | 2019 |
| Revisiting the role of neurotransmitters in epilepsy: An updated review E Akyuz, AK Polat, E Eroglu, I Kullu, E Angelopoulou, YN Paudel Life sciences 265, 118826, 2021 | 143 | 2021 |
| miR-124 and Parkinson’s disease: A biomarker with therapeutic potential E Angelopoulou, YN Paudel, C Piperi Pharmacological Research 150, 104515, 2019 | 93 | 2019 |
| Emerging neuroprotective effect of metformin in Parkinson’s disease: A molecular crosstalk YN Paudel, E Angelopoulou, C Piperi, MF Shaikh, I Othman Pharmacological research 152, 104593, 2020 | 66 | 2020 |
| HMGB1-mediated neuroinflammatory responses in brain injuries: potential mechanisms and therapeutic opportunities YN Paudel, E Angelopoulou, C Piperi, I Othman, MF Shaikh International journal of molecular sciences 21 (13), 4609, 2020 | 65 | 2020 |
| B12 as a treatment for peripheral neuropathic pain: a systematic review T Julian, R Syeed, N Glascow, E Angelopoulou, P Zis Nutrients 12 (8), 2221, 2020 | 63 | 2020 |
| Potential neuroprotective effect of the HMGB1 inhibitor glycyrrhizin in neurological disorders YN Paudel, E Angelopoulou, B Semple, C Piperi, I Othman, MF Shaikh ACS chemical neuroscience 11 (4), 485-500, 2020 | 63 | 2020 |
| Neuroprotective potential of chrysin in Parkinson's disease: Molecular mechanisms and clinical implications E Angelopoulou, ES Pyrgelis, C Piperi Neurochemistry international 132, 104612, 2020 | 63 | 2020 |
| DPP-4 inhibitors: a promising therapeutic approach against Alzheimer’s disease E Angelopoulou, C Piperi Annals of translational medicine 6 (12), 2018 | 55 | 2018 |
| Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression E Angelopoulou, C Piperi, C Adamopoulos, AG Papavassiliou Journal of molecular medicine 94, 867-874, 2016 | 48 | 2016 |
| APOE genotype and Alzheimer’s disease: the influence of lifestyle and environmental factors E Angelopoulou, YN Paudel, SG Papageorgiou, C Piperi ACS chemical neuroscience 12 (15), 2749-2764, 2021 | 47 | 2021 |
| High‐mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches E Angelopoulou, C Piperi, AG Papavassiliou Journal of neurochemistry 146 (3), 211-218, 2018 | 46 | 2018 |
| Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities E Angelopoulou, YN Paudel, C Piperi, A Mishra Journal of biochemical and molecular toxicology 35 (4), e22720, 2021 | 41 | 2021 |
| Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson’s disease: Potential clinical and therapeutic implications E Angelopoulou, YN Paudel, MF Shaikh, C Piperi Pharmacological research 158, 104930, 2020 | 40 | 2020 |
| Environmental impact on the epigenetic mechanisms underlying Parkinson’s disease pathogenesis: a narrative review E Angelopoulou, YN Paudel, SG Papageorgiou, C Piperi Brain Sciences 12 (2), 175, 2022 | 39 | 2022 |
| Emerging role of plexins signaling in glioma progression and therapy E Angelopoulou, C Piperi Cancer Letters 414, 81-87, 2018 | 38 | 2018 |
| Emerging role of S100B protein implication in Parkinson’s disease pathogenesis E Angelopoulou, YN Paudel, C Piperi Cellular and Molecular Life Sciences 78, 1445-1453, 2021 | 36 | 2021 |
| Neuroprotective potential of chrysin: Mechanistic insights and therapeutic potential for neurological disorders A Mishra, PS Mishra, R Bandopadhyay, N Khurana, E Angelopoulou, ... Molecules 26 (21), 6456, 2021 | 33 | 2021 |
| Enlightening the neuroprotective effect of quercetin in epilepsy: From mechanism to therapeutic opportunities E Akyuz, YN Paudel, AK Polat, HE Dundar, E Angelopoulou Epilepsy & Behavior 115, 107701, 2021 | 33 | 2021 |
